The Protecting Access to Medicare Act of 2014 (PAMA) puts more pressure on laboratories as reimbursements are expected to dwindle, yet laboratory testing continues to be at the heart of patient diagnosis and treatment planning. The question, then, is in which labs will that testing take place? With the current industry in flux—shifting to value-based care—it becomes more important than ever for labs to “step up their game” and demonstrate their value beyond lab results.
“There is a very urgent need for laboratories to establish value in the eyes of their owners. One way or another, the laboratory has to be an asset to its owner, whether through earning revenue via traditional fee-for-service or through contribution to bundled care or capitated arrangements. In either scenario, the lab is on the line to demonstrate its contribution and why it should be an essential part of that organization.” –Bob McGonnagle, Publisher, CAP TODAY |
Archives
November 2020
Categories
All
|